Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b

S. Markovic-Plese, B. Bielekova, N. Kadom, T. P. Leist, R. Martin, J. A. Frank, H. F. McFarland

Research output: Contribution to journalArticle

Abstract

An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).

Original languageEnglish (US)
Pages (from-to)1849-1851
Number of pages3
JournalNeurology
Volume60
Issue number11
StatePublished - Jun 10 2003
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Markovic-Plese, S., Bielekova, B., Kadom, N., Leist, T. P., Martin, R., Frank, J. A., & McFarland, H. F. (2003). Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b. Neurology, 60(11), 1849-1851.